Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Gregory Oakhill (NPI 1356312466)

Field	Value
Entity Type	Individual
Organization	Gregory Oakhill
Address	3232 N Northhills Blvd
City	Fayetteville
State	AR
ZIP	72703
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 27, 2006

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the dataset: Total Medicare revenue is $2.8M while Total Medicaid revenue is none, indicating no Medicaid billing on file and a practice that, at least in the submitted data, depends exclusively on Medicare fee‑for‑service. Analysts should treat commercial and Medicaid activity as absent or not captured rather than distributed across payers.

Revenue is heavily concentrated in oncology immunotherapies and related infusions: J9271 (pembrolizumab) generated $882K (36.0% of Medicare revenue), J9299 (nivolumab) generated $380.2K (15.5%), and J1561 (immune globulin) generated $198.1K (8.1%); the precomputed top‑3 codes account for 59.7% of this provider's Medicare revenue. This mix signals a practice whose margins and patient mix are driven by high‑cost biologic infusions.

Operationally the code mix points to a full‑service oncology infusion practice that also manages systemic chemotherapy and supportive care: chemotherapy administration code 96413 appears among top codes, and supportive agents and biosimilars such as Q5108 (pegfilgrastim biosimilar), J0885 (epoetin alfa), Q5106 (epoetin biosimilar) and Q5118 (bevacizumab biosimilar) are billed, reflecting integrated infusion and supportive treatment workflows. Frequent lab monitoring codes (80053, 85025, 82784, 83735) further support this being an active treatment center with routine medical oncology monitoring.

Imaging and diagnostic procedure volumes are an outlier feature of this profile: 74178 ranks #13 of 11397 (100th percentile; extreme outlier) and 70491 ranks #17 of 6170 (100th percentile; extreme outlier), while 71260 ranks at the 99th percentile (noted as extreme outlier). These extreme national percentile positions indicate the provider reports very high volumes for CT/MRI imaging tied to oncologic assessment, suggesting either onsite imaging capabilities or a billing relationship that captures substantial imaging activity.

Competitive standing on the principal immunotherapy agents is not dominant nationally despite high revenue share: J9271 ranks #346 of 1841 (81th percentile; typical, unremarkable volume for this code) and J9299 ranks #228 of 505 (55th percentile; typical, unremarkable volume for this code), which characterizes the provider as a meaningful but not market‑leading user of these agents at the national level. Conversely, for several evaluation and management and imaging codes the provider is well above typical national volume—99214 ranks in the 97th percentile (notably above typical) and 99215 in the 99th percentile (extreme outlier)—pointing to a clinic with heavy visit intensity.

Biosimilar utilization is present but not uniformly large: Q5115 (rituximab‑abbs) and Q5118 (bevacizumab‑bvzr) appear in the top codes, though Q5115 is listed with a low national rank (#78 of 79, 1th percentile) and labeled as typical, unremarkable volume for that code. This pattern suggests the practice uses biosimilars alongside originator agents but does not appear as a major national center for biosimilar administration.

Tenure is long enough to imply established referral patterns: the NPI was enumerated 2006‑01‑27 (~20 years ago), indicating roughly two decades of billing history under this provider identifier, which supports interpreting current high‑volume imaging and infusion patterns as sustained operational behavior rather than a transient spike.

For payer strategy and contracting, the combination of concentrated revenue in high‑cost immunotherapies (59.7% from the top three codes), extreme imaging volumes, and near‑absence of Medicaid activity suggests payers should treat this entity as a Medicare‑centered oncology infusion and imaging provider with limited Medicaid exposure; network decisions or rate negotiations should weigh high oncology drug spend and unusually high diagnostic imaging utilization in this provider's claims mix.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

117 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	21,000	$40	$882K
J9299	Injection, nivolumab, 1 mg	15,840	$20	$380.2K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	5,210	$40	$198.1K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	170	$1,000	$172.7K
J0897	Injection, denosumab, 1 mg	9,120	$20	$164.2K
74178	The provider performs computed tomography of the abdomen and pelvis without contrast material in one or both body regions followed by contrast material in one or both body regions and additional…	480	$180	$84.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	860	$90	$74.4K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	500	$130	$63.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	490	$90	$42.5K
71260	In this diagnostic procedure, the provider performs a computed tomography, or CT, examination of the thorax using contrast material.	480	$80	$37.1K

Showing 1–10 of 117

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 117 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Gregory Oakhill — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

117 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	19	40	20,700	$40	$896.3K
J9299	15	30	15,660	$20	$432.9K
J1561	9	10	5,930	$40	$216.4K
Q5115	20	20	2,800	$30	$95.9K
J0897	27	160	2,580	$20	$89.7K
78815	35	100	90	$550	$83.7K
Q5118	9	10	2,110	$20	$64.3K
J0885	24	40	4,070	$10	$38K
96413	33	80	380	$90	$36.6K
A9552	20	40	180	$150	$28.9K

Showing 1–10 of 117

Related Providers

Other providers that share a Tax Identification Number (TIN) with Gregory Oakhill, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Shore Hematology Oncology Associates PC	NY	Specialist	$0	$61.9M
Highlands Oncology Group PA	AR	Hematology & Oncology Physician	$0	$5.7M
Matthew Lockwood	AR	Hematology & Oncology Physician	$4.2M	$0
Eric Schaefer	AR	Hematology & Oncology Physician	$3.6M	$0
Patrick Travis	AR	Hematology & Oncology Physician	$3.3M	$0
K'anne Arthur	AR	Hematology & Oncology Physician	$3.2M	$0
Stephan Rosenfeld	AR	Hematology & Oncology Physician	$2.3M	$0
J Beck	AR	Hematology & Oncology Physician	$2.2M	$0
Dmitriy Zak	AR	Hematology & Oncology Physician	$2.2M	$0
Mitchell Ross	AR	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as Gregory Oakhill, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sanders, Tompkins, Schiro, Landers And Sanders PLLC	AR	Pediatric Dentistry	$0	$30.4M
Children's Therapy Services, Inc.	AR	Pediatric Physical Therapist	$0	$29.2M
Life Styles Inc.	AR	Case Management Agency	$0	$19.6M
Washington Regional Medical Center	AR	General Acute Care Hospital	$0	$10.9M
Cross Therapy Services, Ltd	AR	Pediatric Occupational Therapist	$0	$5.8M
Medical Associates Of Northwest Arkansas PA	AR	Pediatrics Physician	$0	$5.8M
Oral & Facial Surgery Center PA	AR	Oral and Maxillofacial Surgery (Dentist)	$0	$4.8M
Thomas A. Sarna, Dds PLLC	AR	Oral and Maxillofacial Surgery Clinic/Center	$0	$3.4M
Washington Regional Medical System	AR	Hospitalist Physician	$0	$3.4M
The Therapy Spot,llc	AR	Speech-Language Pathologist	$0	$3.2M

Gregory Oakhill — Billing Profile & Reimbursement Data

Sign up for Gregory Oakhill — Billing Profile & Reimbursement Data policy alerts

Gregory Oakhill — Billing Profile & Reimbursement Data

Sign up for Gregory Oakhill — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References